Evaluation of Hypoxia by EF5 (NSC#684681) Binding in Cervix Cancer
- Determine the relationship between the level of EF5 binding and pretreatment hemoglobin
level, tumor size, and stage of disease in patients with stage IIB, IIIB, or IVA
- Determine whether pretreatment tumor hypoxia (measured by EF5 binding) is associated
with overall survival, progression-free interval, and local control in these patients.
- Determine the relationship between EF5 binding and CD-31 labeling (tumor vasculature)
and Ki-67 labeling (cellular proliferation) in these patients.
OUTLINE: This is a multicenter study.
Patients receive EF5 IV over 1-2.5 hours on day 1. Tumor hypoxia is measured using
immunohistochemical techniques. Biopsies are collected 1-2 days later. Blood is collected
before EF5 is administered and again at the time of surgery.
Patients are followed approximately 1 month after surgery.
PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study within 3 years.
Masking: Open Label, Primary Purpose: Diagnostic
Gillian M. Thomas, BSc, MD, FRCPC, FRCR (Hon)
Odette Cancer Centre at Sunnybrook
United States: Federal Government
|Ellis Fischel Cancer Center at University of Missouri - Columbia||Columbia, Missouri 65203|
|Arkansas Cancer Research Center at University of Arkansas for Medical Sciences||Little Rock, Arkansas 72205|
|Oklahoma University Medical Center||Oklahoma City, Oklahoma 73104|
|Cancer Care Associates - Midtown Tulsa||Tulsa, Oklahoma 74104|
|Colorado Gynecologic Oncology Group P.C.||Aurora, Colorado 80010|